News Releases

Below are the latest News Releases for Clearmind Medicine Inc.

9

February

2022

Clearmind Medicine announces Share-Based Compensation Plan
Read More
8

February

2022

Clearmind Medicine Secures CAD$1.6 Million in Private Placement
Read More
31

January

2022

Clearmind Medicine Now Fully Eligible for Settlement through the Depository Trust Company (“DTC”)
Read More
28

January

2022

Clearmind Medicine Partners with Dr. Gabor Maté to Discuss Alcohol Use Disorder and Trauma in a Special Virtual Event on Feb 3
Read More
19

January

2022

Clearmind Medicine to Host “Psychedelics for Alcoholism: From Molecule to Medicine” Virtual Event on January 26
Read More
13

January

2022

Mark Haden, Clearmind Medicine's VP of Business Development Presented at The Canadian Psychedelics Association Event
Read More
11

January

2022

Clearmind Medicine Strengthens Presence in North America with New Senior Appointments
Read More
24

November

2021

Clearmind Medicine Launches Study for Binge Eating with The Hebrew University Using its Proprietary MEAI Compound
Read More
22

November

2021

Clearmind Medicine to Pursue Dual Listing on Nasdaq
Read More
18

November

2021

Clearmind Medicine Engages Bar-Ilan University to Evaluate Anti-Addictive Properties of Clearmind's Proprietary MEAI Compound
Read More
8

November

2021

Clearmind Medicine Announces Sponsorship of Wonderland Psychedelic Conference in Miami
Read More
26

October

2021

Clearmind Signs Development and Supply Agreement to Produce its Drug Candidate MEAI Psychedelic Molecule With Aragen Life Sciences
Read More
14

October

2021

Clearmind Medicine Appoints Distinguished Addiction Experts
Read More
13

October

2021

Clearmind Medicine Files Provisional Patent Application
Read More
7

October

2021

Clearmind Medicine Partners With Clinipace
Read More